Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||05/03/2018|
|Rapid review completed||21/05/2018|
|Rapid Review outcome||A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Natpar compared with the current standard of care.|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.